ClinicalTrials.gg

How we know

Every link on this study, and who decided it

The study on the left, the conditions and drugs this site links it to, and on each link the judgments that made or checked it, by day and by judge. The top row is the record itself: each new version seen since tracking began. Dashed lines are links the registry record does not make itself. Select a link to see everything judged on it, or a mark for one decision with its reason and evidence.

4 links0 made here, not in the record12 judgments2 judges (the rules as one: Rule based)1 record change seen1 read an older version
Claude Opus 5.5Rule basedRecord updated on ClinicalTrials.govReplaced, or read an older version
Oct 19Oct 26Nov 2Nov 9Nov 16TodayNCT04586231A Study of Belzutifan(MK-6482) in CombinationWith Lenvatinib VersusCabozantinib for Treatmentof Renal Cell Carcinoma(MK-6482-011)Merck Sharp & Dohme LLCPhase 3 · active not recruitinRECORDThe record itselfVersions seen nightly since Sep 25, 2…›Nov 6 · ClinicalTrials.gov record · Version of 2026-11-06Nov 6 · Rule based · Reading set asideNov 10 · Rule based · Read againRead againCONDITIONSCarcinoma, Renal CellThe registry's MeSH filing›Nov 14 · Rule based · Finest filed termAs of now · Rule based · Main conditionMain conditionDRUGSBelzutifanIntervention entry›Nov 2 · Claude Opus 5.5 · TestedNov 10 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedLenvatinibIntervention entry›Nov 2 · Claude Opus 5.5 · BackgroundNov 18 · Rule based · TestedTestedCabozantinibIntervention entry›Nov 2 · Claude Opus 5.5 · ComparatorNov 10 · Claude Opus 5.5 · ComparatorNov 18 · Rule based · ComparatorComparator

Times are in your time zone; a day marked “day only” kept no time. The graph scrolls sideways on a narrow screen; every mark is also in the list below.

Belzutifan

From the registry record3 judgments on this link
Role in the study, from the registry to what was judged
RegistryEntry “Belzutifan”the record gives no role
→judged=agrees=agrees
How the 3 judgments split100%of judgments with a known value say Tested
Tested · 3

All judgments on this study

WhenLinkJudgeDecisionState
Nov 2BelzutifanClaude Opus 5.5TestedReplaced
Nov 2LenvatinibClaude Opus 5.5BackgroundRead an older version
Nov 2CabozantinibClaude Opus 5.5ComparatorReplaced
Nov 6The record itselfClinicalTrials.gov recordVersion of 2026-11-06Record change
Nov 6The record itselfRule based · nightly checkReading set asideCurrent
Nov 10The record itselfRule based · nightly checkRead againCurrent
Nov 10BelzutifanClaude Opus 5.5TestedCurrent
Nov 10CabozantinibClaude Opus 5.5ComparatorCurrent
Nov 14Carcinoma, Renal CellRule based · condition-kind ruleFinest filed termCurrent
Nov 18BelzutifanRule based · role ruleTestedAgrees
Nov 18LenvatinibRule based · role ruleTestedOverridden
Nov 18CabozantinibRule based · role ruleComparatorAgrees
As of nowCarcinoma, Renal CellRule based · main-condition ruleMain conditionCurrent

The rules, in plain words

“Rule based” means one of these decided, not a model or a person. Each runs every night over every study.

Which drugs a study tests

Reads each treatment the study lists and the arms it is in. A drug only in the experimental arm is tested. A drug in every arm while something else changes between the arms is given beside it. A drug only in the control arm is the comparator. Placebo, procedures and usual care are known by name.

Where the whole record has been read, that reading's answer replaces the rule's.

What a study is mainly about

Starts from the first condition ClinicalTrials.gov files the study under. It moves to a narrower one only when the study's own title or listed conditions name it, and sets aside terms the registry often files by mistake. A study open to many cancers is not placed under one of them unless its title names it.

Checked against studies judged one by one; the study page says when it differs from the registry.

How a condition link is counted

For each condition a study is filed under: whether it is the study's own condition at the finest the study states it, a wider one, a general category, or filed by mistake; and whether it is the main condition, a setting the study names, or only how it was filed.

A decision on file for one study overrides it, with who made it and when.

When a study changes after it was read

Every night, studies whose record changed are compared with the last reading. A change to sites or dates leaves the reading as it is; a reworded entry keeps it; a change to the treatments or conditions marks it to be read again.

Until it is read again, the page shows the last reading and says so.